Method for preparing medical intermediate 3-benzimidazoline coumarin pyrone derivative through catalysis of acidic eutectic solvent
By using acid eutectic solvents as catalysts and solvents, the problems of large amount of catalysts used and serious environmental pollution in the preparation of 3-benzimidazoline coumarin pyrone derivatives in the prior art were solved, and efficient production was achieved rate and industrial production.
Patent Information
- Application Number
- CN202411135064.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-29
AI Technical Summary
The preparation method of 3-benzimidazoline coumarin pyrone derivative in the prior art has problems such as large amount of catalyst use, serious environmental pollution, low yield, complex by-products, and difficult to achieve large-scale continuous production of industrialization. .
Using acidic eutectic solvents as catalyst and solvents, the catalytic efficiency and selectivity are improved through simple preparation methods, the amount of catalyst is reduced, the reuse and regeneration of catalysts is realized, environmental pollution is reduced, and the yield of target products and reaction raw materials are improved. utilization rate.
It improves catalytic efficiency and yield, reduces environmental pollution, reduces production costs, and achieves large-scale continuous production in industrialized production.
Smart Images

Figure BDA0004999161040000031 
Figure BDA0004999161040000051 
Figure BDA0004999161040000071
Abstract
Description
Technical Field
[0001] The invention relates to a method for preparing a pharmaceutical intermediate, and in particular to a method for preparing a pharmaceutical intermediate 3-benzimidazolinium coumarin-pyrone derivative by catalysis of an acidic low eutectic solvent, and belongs to the field of biomedicine. Background Art
[0002] Heterocyclic compounds are organic compounds containing heterocyclic structures in the molecule. In addition to carbon atoms, the atoms constituting the ring also contain at least one heteroatom. Heterocyclic compounds are commonly found in a variety of drug molecules, vitamins, many natural products and biomolecules, and most of them have good biological and pharmacological activities. They are often used as key structural units for synthesizing new drugs. Benzimidazolin, as a heterocyclic compound containing dinitrogen, usually has good biological activities such as antihypertension, anti-influenza, treatment of diabetes, enzyme inhibitors, etc., and has very important reference value for medical and biological research. In addition, compounds containing pyranochromenone structures are also an important class of heterocyclic compounds, containing very important active substances and having a wide spectrum of biological activities, such as insecticide, bactericidal, herbicidal, antiviral, anticancer, etc. Therefore, 3-benzimidazolin-coumarin-pyrone derivatives (also known as 3-benzimidazolin-pyranochromenone) containing both benzimidazolin-pyranochromenone and two important active unit structures have more extensive biological and pharmacological activities, and its preparation has attracted extensive attention from drug synthesizers.
[0003] In traditional chemical synthesis, the preparation of 3-benzimidazolinium coumarin pyrone derivatives usually adopts a multi-step synthesis method. The route of this synthesis method is long and the reaction conditions are harsh, cumbersome and complicated, resulting in relatively low yield and purity of the product, serious environmental pollution and difficulty in achieving industrial large-scale continuous production. Based on the various advantages of the "one-pot method" for preparing organic compounds, the use of a multi-component "one-pot method" for the preparation of 3-benzimidazolinium coumarin pyrone derivatives can not only reduce the use of volatile organic solvents, the number of intermediates and the complexity of purification, but also reduce the degree of environmental pollution during its preparation process. It has a higher cost-effectiveness and can theoretically achieve its large-scale sustainable production.
[0004] Based on the above considerations, Wang Xiang et al. from Huaiyin Normal University reported a three-component tandem cyclization reaction of aromatic aldehydes, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin promoted by acetic acid. The reaction was carried out at 80°C for 1 hour, and a series of novel 3-benzimidazolinium coumarin and pyrone derivatives were obtained with a yield of 58-84%. The reaction does not require any additives and the post-treatment only requires simple filtration and washing to conveniently obtain pure 3-benzimidazolinium coumarin and pyrone derivatives (Synthesis of 3-Benzo[d]imidazoline-substituted pyrano[3,2-c]chromen-2-one derivatives by three-component tandem reaction [J], Organic Chemistry, 2021, 41: 1241-1245). However, the above preparation method also has many problems, such as: 1. Acetic acid, which is used as a catalyst and promoter, is used in large quantities; 2. The acetic acid in the preparation process cannot be reused and regenerated, resulting in a large amount of waste acid generated in the entire preparation process and serious environmental pollution; 3. The catalytic efficiency and selectivity of acetic acid are poor, resulting in complex and diverse by-products, a low yield of the target product 3-benzimidazolinylcoumarin pyrone derivative and a long reaction time; 4. The entire preparation process cannot be mass-produced continuously and is difficult to industrialize.
[0005] A low eutectic solvent is a low eutectic mixture formed by combining a quaternary ammonium salt and a hydrogen bond donor according to a certain stoichiometry, and its freezing point is significantly lower than the melting point of each pure substance component. Since it has almost all the advantages of ionic liquids, and the raw materials are cheap, the synthesis process is simple, the atomic utilization rate is 100%, it is non-toxic, and it is biodegradable, so low eutectic solvents have been widely used in the fields of synthesis, separation, electrochemistry, etc. In addition, as one of the low eutectic solvents, acidic low eutectic solvents can be used in organic synthesis because of their acidity to replace traditional inorganic or organic acid catalysts. Based on this, this case intends to use an acidic low eutectic solvent as a solvent and catalyst in the preparation process of the drug intermediate 3-benzimidazolinium coumarin and pyrone derivatives, thereby avoiding the above-mentioned problems caused by using acetic acid as a promoter. Summary of the invention
[0006] Aiming at the problems of low raw material utilization rate, long reaction time, low target product yield, complex and diverse by-products, and serious environmental pollution caused by large amount of catalyst used and non-reusable catalyst in the preparation method of the drug intermediate 3-benzimidazolinium coumarin pyrone derivative in the prior art, the present invention provides a method for preparing the drug intermediate 3-benzimidazolinium coumarin pyrone derivative by catalysis of an acidic deep eutectic solvent. The method uses an acidic deep eutectic solvent which is simple to prepare, has high catalytic efficiency and selectivity, can be reused and regenerated, and is easy to biodegrade as a solvent and catalyst, can effectively improve the catalytic efficiency of the catalyst, reduce the amount of catalyst used, improve the utilization rate of the reaction raw materials and the yield of the target product, and reduce environmental pollution, and is convenient for industrial large-scale continuous production while saving production costs.
[0007] The purpose of the present invention can be achieved through the following technical solutions:
[0008] A method for preparing a pharmaceutical intermediate 3-benzimidazolinium coumarin pyrone derivative catalyzed by an acidic deep eutectic solvent, wherein the chemical reaction formula of the preparation method is:
[0009]
[0010] And the preparation method also comprises the following steps:
[0011] Step 1: adding a preset amount of an acidic deep eutectic solvent into a flask equipped with a magnetic stirrer, a thermometer and a spherical condenser, and then adding a preset amount of aromatic aldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin, and stirring and mixing at room temperature;
[0012] Step 2: Heat the reaction solution to 65-90°C in an oil bath while stirring, then keep the reaction at this temperature until the raw material point disappears, immediately stop stirring and heating, and keep the reaction for 27-46 minutes;
[0013] Step 3: After the reaction solution is naturally cooled to room temperature, ethanol is added, the mixture is allowed to stand and filtered to separate the solid product, and the solid product is vacuum dried at 80° C. to a constant weight to obtain a 3-benzimidazolinylcoumarin-pyrone derivative.
[0014] Optionally, the aromatic aldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin in the step 1 are used in a molar ratio of 1:1:1.
[0015] Optionally, the acidic deep eutectic solvent is used in an amount in milliliters that is 6 to 11 times the molar amount of the aromatic aldehyde in millimoles.
[0016] Optionally, the acidic low eutectic solvent is obtained by directly heating polyethylene glycol 200 and p-toluenesulfonic acid, wherein the molar ratio of polyethylene glycol 200 to p-toluenesulfonic acid is 1:2.
[0017] Optionally, the aromatic aldehyde is any one of benzaldehyde, p-bromobenzaldehyde, m-bromobenzaldehyde, o-bromobenzaldehyde, p-chlorobenzaldehyde, m-methoxybenzaldehyde, 2,4-dichlorobenzaldehyde, and 3,4-dichlorobenzaldehyde.
[0018] Optionally, the filtrate obtained by filtration in step 3 is subjected to rotary distillation at a temperature of 85° C. to remove ethanol, and then the acidic low eutectic solvent is reused in the next round according to steps 1 to 3;
[0019] During the repeated use of the acidic deep eutectic solvent, if the purity of the product 3-benzimidazolinium coumarin pyrone derivative is lower than 98% or the yield is reduced by more than 5% compared with the first use, the repeated use of the acidic deep eutectic solvent is stopped and it is regenerated.
[0020] Optionally, the method for regenerating the acidic deep eutectic solvent is as follows:
[0021] A preset volume of ethyl acetate is added to the acidic low eutectic solvent which cannot be reused, and the mixture is refluxed under stirring for 30 minutes, and then the liquid is separated to collect the lower layer of liquid. Then, the same volume of ethyl acetate is added thereto, and the mixture is refluxed under stirring for another 30 minutes, and then the liquid is separated again to collect the lower layer of liquid. The washing operation is performed three times in sequence, and the lower layer of liquid obtained for the third time is vacuum dried at a temperature of 75°C for 6 hours to obtain a regenerated acidic low eutectic solvent.
[0022] Optionally, the volume of ethyl acetate used in the regeneration process of the acidic deep eutectic solvent is 3 to 5 times the volume of the acidic deep eutectic solvent.
[0023] Beneficial effects of the present invention:
[0024] (1) The method for preparing the pharmaceutical intermediate 3-benzimidazolinium coumarin-pyrone derivative provided by the present invention uses an acidic deep eutectic solvent as a catalyst and solvent. Compared with acetic acid as a promoter, the acidic deep eutectic solvent has a higher catalytic activity for the reaction of aromatic aldehydes, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin to prepare 3-benzimidazolinium coumarin-pyrone derivatives. Therefore, the reaction time can be effectively shortened while improving the product yield.
[0025] (2) According to the method for preparing the pharmaceutical intermediate 3-benzimidazolinium coumarin-pyrone derivative provided by the present invention, the acidic low eutectic solvent can be directly reused after the product and ethanol are separated successively after the reaction is completed, without any further treatment; and the loss amount during the repeated use is small, so it can be reused multiple times, which improves the economic benefits and facilitates the industrial large-scale production of the pharmaceutical intermediate 3-benzimidazolinium coumarin-pyrone derivative.
[0026] (3) The method for preparing the pharmaceutical intermediate 3-benzimidazolinium coumarin pyrone derivative provided by the present invention reduces the generation of waste acid during the preparation process because the acidic deep eutectic solvent can be reused, thereby reducing the production cost and environmental pollution. In addition, since the unreacted raw materials can participate in the subsequent reuse along with the reuse of the acidic deep eutectic solvent, the utilization efficiency of the reaction raw materials is greatly improved. DETAILED DESCRIPTION
[0027] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0028] The hydrogen and carbon nuclear magnetic resonance characterizations of the reaction products 3-benzimidazolinium coumarin pyrone derivatives in the following examples were performed using a nuclear magnetic resonance instrument of model AVANCE 400MHz from Bruker, Germany; the HPLC purity was determined using a HPLC instrument of model LC-2050 from Shimadzu, Japan. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.
[0029] A method for preparing a pharmaceutical intermediate 3-benzimidazolinium coumarin pyrone derivative catalyzed by an acidic deep eutectic solvent, wherein the chemical reaction formula of the preparation method is:
[0030]
[0031] And the preparation method also comprises the following steps:
[0032] Step 1: adding a preset amount of an acidic deep eutectic solvent into a flask equipped with a magnetic stirrer, a thermometer and a spherical condenser, and then adding a preset amount of aromatic aldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin, and stirring and mixing at room temperature;
[0033] Step 2: Heat the reaction solution to 65-90°C in an oil bath while stirring, then keep the reaction at this temperature until the raw material point disappears, immediately stop stirring and heating, and keep the reaction for 27-46 minutes;
[0034] Step 3: After the reaction solution is naturally cooled to room temperature, ethanol is added, the mixture is allowed to stand and filtered to separate the solid product, and the solid product is vacuum dried at 80° C. to a constant weight to obtain a 3-benzimidazolinylcoumarin-pyrone derivative.
[0035] As a technical optimization scheme of the present invention, the molar ratio of the aromatic aldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin in the step 1 is 1:1:1.
[0036] As a technical optimization solution of the present invention, the volume of the acidic low eutectic solvent used in milliliters is 6 to 11 times the molar amount of the aromatic aldehyde in millimoles.
[0037] As a technical optimization solution of the present invention, the acidic low eutectic solvent is obtained by directly heating polyethylene glycol 200 and p-toluenesulfonic acid, wherein the molar ratio of polyethylene glycol 200 to p-toluenesulfonic acid is 1:2.
[0038] As a technical optimization scheme of the present invention, the aromatic aldehyde is any one of benzaldehyde, p-bromobenzaldehyde, m-bromobenzaldehyde, o-bromobenzaldehyde, p-chlorobenzaldehyde, m-methoxybenzaldehyde, 2,4-dichlorobenzaldehyde and 3,4-dichlorobenzaldehyde.
[0039] As a technical optimization scheme of the present invention, the filtrate obtained by suction filtration in step 3 is subjected to rotary distillation at a temperature of 85° C. to remove ethanol, and then the acidic low eutectic solvent is reused in the next round according to steps 1 to 3;
[0040] During the repeated use of the acidic deep eutectic solvent, if the purity of the product 3-benzimidazolinium coumarin pyrone derivative is lower than 98% or the yield is reduced by more than 5% compared with the first use, the repeated use of the acidic deep eutectic solvent is stopped and it is regenerated.
[0041] As a technical optimization solution of the present invention, the method for regenerating the acidic deep eutectic solvent is as follows:
[0042] A preset volume of ethyl acetate is added to the acidic low eutectic solvent which cannot be reused, and the mixture is refluxed under stirring for 30 minutes, and then the liquid is separated to collect the lower layer of liquid. Then, the same volume of ethyl acetate is added thereto, and the mixture is refluxed under stirring for another 30 minutes, and then the liquid is separated again to collect the lower layer of liquid. The washing operation is performed three times in sequence, and the lower layer of liquid obtained for the third time is vacuum dried at a temperature of 75°C for 6 hours to obtain a regenerated acidic low eutectic solvent.
[0043] As a technical optimization solution of the present invention, the volume usage of ethyl acetate used in the regeneration process of the acidic low eutectic solvent is 3 to 5 times the volume of the acidic low eutectic solvent used.
[0044] It is worth noting that the specific reaction process parameters in the present invention, such as reaction temperature, insulation reaction time, and reaction raw material ratio, are crucial to the yield and purity of the obtained product. The inventors have optimized the above process parameters through a large number of experiments and combined with the preparation principles and characteristics of 3-benzimidazolinium coumarin pyrone derivatives, so as to effectively ensure that the catalytic activity of the acidic deep eutectic solvent is best exerted, improve its catalytic selectivity, reduce the occurrence of side reactions, and thus help to ensure that the yield and purity of the obtained product meet the requirements, and improve the reusability of the acidic deep eutectic solvent.
[0045] The preparation process of the acidic low eutectic solvent used in the present invention refers to relevant literature (Qin Shumiao, Research on the Removal of Basic Nitrogen and Non-Basic Nitrogen Performance of Acidic Low Eutectic Solvents [D], Liaoning Shihua University, 2020, page 20).
[0046] The present invention is further described below in conjunction with specific embodiments.
[0047] Example 1
[0048] Preparation of 3-(1H-benzo[d]imidazoline)-4-phenyl-3,4-dihydropyrano[3,2-c]chromene-2,5-dione
[0049]
[0050] The operation steps of this embodiment are as follows:
[0051] 1) Add 1.0 mmol benzaldehyde, 1.0 mmol 2-cyanomethylbenzimidazole and 1.0 mmol 4-hydroxycoumarin to a 50 mL three-necked flask with a spherical condenser, a thermometer and a magnetic stirrer containing 7 mL of an acidic deep eutectic solvent, and stir at room temperature until the mixture is uniform.
[0052] 2) Heat the three-necked flask in an oil bath under magnetic stirring, uniformly raise the temperature to 74°C, and maintain this temperature for 38 minutes. When the raw material spot disappears as detected by TLC (thin plate chromatography), the reaction is complete, and heating and stirring are stopped.
[0053] 3) The reaction solution was cooled to room temperature naturally, 10 mL of ethanol was added, and the mixture was allowed to stand for 4 hours. The solid product was crushed and dried under vacuum at 80°C to constant weight, weighing 0.35 g. The main substance was identified by the HPLC retention value method as the target product 3-(1H-benzo[d]imidazoline)-4-phenyl-3,4-dihydropyran[3,2-c]chromene-2,5-dione, with a purity of 99.1%. The reaction yield was calculated to be 86%. After the filtrate was evaporated at 85°C to remove the ethanol, benzaldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin were directly added to carry out the next reaction.
[0054] The structural characterization data of the product 3-(1H-benzo[d]imidazoline)-4-phenyl-3,4-dihydropyrano[3,2-c]chromene-2,5-dione obtained in this example are as follows: light yellow solid; 1 H NMR (400 MHz, DMSO-d 6 ): δ=5.08 (s, 1H), 7.07~7.41 (m, 8H), 7.49 (d, J=7.5Hz, 3H), 7.62 (t, J=7.8Hz, 1H), 7.88 (d, J=8.2Hz, 1H), 12.05 (s, 2H); 13 C NMR (100 MHz, DMSO-d 6 ): δ=160.9, 159.9, 156.2, 152.3, 151.8, 144.7, 132.1, 128.2, 127.2, 126.8, 124.6, 122.7, 122.4, 116.4, 114.3, 105.7, 66.9, 36.5.
[0055] Example 2
[0056] Preparation of 3-(1H-benzo[d]imidazoline)-4-(2-bromophenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione
[0057]
[0058] The operation steps of this embodiment are as follows:
[0059] 1) Add 1.0 mmol o-bromobenzaldehyde, 1.0 mmol 2-cyanomethylbenzimidazole and 1.0 mmol 4-hydroxycoumarin to a 50 mL three-necked flask with a spherical condenser, a thermometer and a magnetic stirrer containing 6 mL of an acidic deep eutectic solvent, and stir at room temperature until the mixture is uniform.
[0060] 2) Heat the three-necked flask in an oil bath under magnetic stirring, uniformly raise the temperature to 65° C., and maintain this temperature for 27 min. When the raw material spot disappears as detected by TLC (thin plate chromatography), the reaction is complete, and heating and stirring are stopped.
[0061] 3) The reaction solution was cooled to room temperature naturally, 8 mL of ethanol was added, and the mixture was allowed to stand for 4 h. The solid product was crushed and dried under vacuum at 80 ° C to constant weight, weighing 0.44 g. The main substance was identified by the HPLC retention value method as the target product 3-(1H-benzo[d]imidazoline)-4-(2-bromophenyl)-3,4-dihydropyran[3,2-c]chromene-2,5-dione, with a purity of 99.3%. The reaction yield was calculated to be 90%. After the filtrate was evaporated at 85 ° C to remove the ethanol, o-bromobenzaldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin were directly added to carry out the next reaction.
[0062] The structural characterization data of the product 3-(1H-benzo[d]imidazoline)-4-(2-bromophenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione obtained in this example are as follows: yellow solid; 1 H NMR (400 MHz, DMSO-d 6 ): δ=5.36 (s, 1H), 7.11~7.18 (m, 3H), 7.39~7.51 (m, 6H), 7.72 (t, J=8.6Hz, 1H), 7.94 (d, J=8.2Hz, 1H), 8.03 (d, J=7.8Hz, 1H), 11.71 (s, 2H); 13 C NMR (100 MHz, DMSO-d 6 ): δ=161.1, 160.2, 157.9, 153.4, 152.0, 141.2, 135.0, 134.4, 132.8, 131 .1, 129.6, 127.0, 124.7, 123.8, 121.4, 116.4, 113.9, 111.8, 101.2, 67.4.
[0063] Example 3
[0064] Preparation of 3-(1H-benzo[d]imidazoline)-4-(3-bromophenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione
[0065]
[0066] The operation steps of this embodiment are as follows:
[0067] 1) Add 1.0 mmol m-bromobenzaldehyde, 1.0 mmol 2-cyanomethylbenzimidazole and 1.0 mmol 4-hydroxycoumarin to a 50 mL three-necked flask with a spherical condenser, a thermometer and a magnetic stirrer containing 6 mL of an acidic deep eutectic solvent, and stir at room temperature until the mixture is uniform.
[0068] 2) Heat the three-necked flask in an oil bath under magnetic stirring, uniformly raise the temperature to 69° C., and maintain this temperature for 32 min. When the raw material spot disappears as detected by TLC (thin plate chromatography), the reaction is complete, and heating and stirring are stopped.
[0069] 3) The reaction solution was cooled to room temperature naturally, 8 mL of ethanol was added, and the mixture was allowed to stand for 4 h. The solid product was crushed and dried under vacuum at 80 °C to constant weight, weighing 0.41 g. The main substance was identified by the HPLC retention value method as the target product 3-(1H-benzo[d]imidazoline)-4-(3-bromophenyl)-3,4-dihydropyran[3,2-c]chromene-2,5-dione, with a purity of 99.0%. The reaction yield was calculated to be 83%. After the filtrate was evaporated at 85 °C to remove the ethanol, m-bromobenzaldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin were directly added to carry out the next reaction.
[0070] The structural characterization data of the product 3-(1H-benzo[d]imidazoline)-4-(3-bromophenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione obtained in this example are as follows: light yellow solid; 1 H NMR (400 MHz, DMSO-d 6 ): δ=5.09 (s, 1H), 7.13~7.25 (m, 3H), 7.31~7.40 (m, 4H), 7.48~7.65 (m, 3H), 7.73 (s, 1H), 7.92 (d, J=7.2Hz, 1H), 12.11 (s, 2H); 13 C NMR (100 MHz, DMSO-d 6 ): δ=160.8, 160.0, 156.2, 152.5, 151.9, 147.3, 132.8, 130.7, 130.2, 129 .7, 126.1, 124.6, 122.9, 122.6, 121.1, 116.2, 114.0, 105.0, 66.6, 36.0.
[0071] Example 4
[0072] Preparation of 3-(1H-benzo[d]imidazoline)-4-(4-bromophenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione
[0073]
[0074] The operation steps of this embodiment are as follows:
[0075] 1) Add 1.0 mmol p-bromobenzaldehyde, 1.0 mmol 2-cyanomethylbenzimidazole and 1.0 mmol 4-hydroxycoumarin to a 50 mL three-necked flask with a spherical condenser, a thermometer and a magnetic stirrer containing 8 mL of an acidic deep eutectic solvent, and stir at room temperature until the mixture is uniform.
[0076] 2) Heat the three-necked flask in an oil bath under magnetic stirring, uniformly raise the temperature to 77° C., and maintain this temperature for 36 min. When the raw material spot disappears as detected by TLC (thin plate chromatography), the reaction is complete, and heating and stirring are stopped.
[0077] 3) The reaction solution was cooled to room temperature naturally, 10 mL of ethanol was added, and the mixture was allowed to stand for 4 h. The solid product was crushed and dried under vacuum at 80 °C to constant weight, weighing 0.39 g. The main substance was identified by the HPLC retention value method as the target product 3-(1H-benzo[d]imidazoline)-4-(4-bromophenyl)-3,4-dihydropyran[3,2-c]chromene-2,5-dione, with a purity of 99.5%. The reaction yield was calculated to be 79%. After the filtrate was evaporated at 85 °C to remove the ethanol, p-bromobenzaldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin were directly added to carry out the next reaction.
[0078] The structural characterization data of the product 3-(1H-benzo[d]imidazoline)-4-(4-bromophenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione obtained in this example are as follows: yellow solid; 1 H NMR (400 MHz, DMSO-d 6 ): δ=5.11(s, 1H), 7.15~7.18(m, 2H), 7.32~7.52(m, 8H), 7.68(t, J=7.6Hz, 1H), 7.95(d, J=7.9Hz, 1H), 12.13(s, 2H); 13 C NMR (100 MHz, DMSO-d 6 ): δ=161.1, 160.2, 156.8, 152.8, 152.3, 144.5, 133.0, 131.6, 130.1, 125.1, 123.2, 123.1, 120.3, 116.9, 114.6, 105.6, 67.3, 36.7, 31.1.
[0079] Example 5
[0080] Preparation of 3-(1H-benzo[d]imidazoline)-4-(4-chlorophenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione
[0081]
[0082] The operation steps of this embodiment are as follows:
[0083] 1) Add 1.0 mmol p-chlorobenzaldehyde, 1.0 mmol 2-cyanomethylbenzimidazole and 1.0 mmol 4-hydroxycoumarin to a 50 mL three-necked flask with a spherical condenser, a thermometer and a magnetic stirrer containing 11 mL of an acidic deep eutectic solvent, and stir at room temperature until the mixture is uniformly mixed.
[0084] 2) Heat the three-necked flask in an oil bath under magnetic stirring, uniformly raise the temperature to 84° C., and maintain this temperature for 41 min. When the raw material spot disappears as detected by TLC (thin plate chromatography), the reaction is complete, and heating and stirring are stopped.
[0085] 3) The reaction solution was cooled to room temperature naturally, 15 mL of ethanol was added, and the mixture was allowed to stand for 4 hours. The solid product was crushed and dried under vacuum at 80°C to constant weight, weighing 0.34 g. The main substance was identified by the HPLC retention value method as the target product 3-(1H-benzo[d]imidazoline)-4-(4-chlorophenyl)-3,4-dihydropyran[3,2-c]chromene-2,5-dione, with a purity of 99.3%. The reaction yield was calculated to be 76%. After the filtrate was evaporated at 85°C to remove the ethanol, p-chlorobenzaldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin were directly added to carry out the next reaction.
[0086] The structural characterization data of the product 3-(1H-benzo[d]imidazoline)-4-(4-chlorophenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione obtained in this example are as follows: yellow solid; 1 H NMR (400 MHz, DMSO-d 6 ): δ=5.10 (s, 1H), 7.09~7.14 (m, 2H), 7.31~7.35 (m, 3H), 7.42 (t, J=7.8Hz, 2H), 7 .54 (d, J=8.2Hz, 3H), 7.65 (t, J=7.6Hz, 1H), 7.93 (d, J=7.6Hz, 1H), 12.12 (s, 2H); 13 C NMR (100 MHz, DMSO-d 6): δ=174.0, 163.5, 162.2, 158.3, 153.8, 153.0, 145.9, 134.3, 133.2, 13 0.9, 130.2, 126.7, 124.8, 124.1, 118.2, 115.9, 107.0, 68.5, 37.9, 23.1.
[0087] Example 6
[0088] Preparation of 3-(1H-benzo[d]imidazoline)-4-(3-methoxyphenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione
[0089]
[0090] The operation steps of this embodiment are as follows:
[0091] 1) Add 1.0 mmol of m-methoxybenzaldehyde, 1.0 mmol of 2-cyanomethylbenzimidazole and 1.0 mmol of 4-hydroxycoumarin to a 50 mL three-necked flask with a spherical condenser, a thermometer and a magnetic stirrer containing 11 mL of an acidic deep eutectic solvent, and stir at room temperature until the mixture is uniformly mixed.
[0092] 2) Heat the three-necked flask in an oil bath under magnetic stirring, uniformly raise the temperature to 90° C., and maintain this temperature for 46 min. When the raw material spot disappears as detected by TLC (thin plate chromatography), the reaction is complete, and heating and stirring are stopped.
[0093] 3) The reaction solution was cooled to room temperature naturally, 15 mL of ethanol was added, and the mixture was allowed to stand for 4 hours. The solid product was crushed and dried under vacuum at 80°C to constant weight, weighing 0.32 g. The main substance was identified by the HPLC retention value method as the target product 3-(1H-benzo[d]imidazoline)-4-(3-methoxyphenyl)-3,4-dihydropyran[3,2-c]chromene-2,5-dione, with a purity of 99.5%. The reaction yield was calculated to be 73%. After the filtrate was evaporated at 85°C to remove the ethanol, m-methoxybenzaldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin were directly added to carry out the next reaction.
[0094] The structural characterization data of the product 3-(1H-benzo[d]imidazoline)-4-(3-methoxyphenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione obtained in this example are as follows: yellow solid; 1 H NMR (400 MHz, DMSO-d 6): δ=3.67 (s, 3H), 5.08 (s, 1H), 6.70 (d, J=8.0Hz, 1H), 7.04 (d, J=7.6Hz, 1H), 7.11~7.15 (m, 4H), 7.29 ( s, 3H), 7.41 (t, J=7.6Hz, 2H), 7.53 (s, 3H), 7.63 (d, J=7.6Hz, 1H), 7.90 (d, J=7.2Hz, 1H), 12.10 (s, 2H); 13 C NMR (100 MHz, DMSO-d 6 ): δ=160.9, 160.1, 159.0, 156.3, 152.8, 152.5, 146.4, 132.2, 129.5, 12 4.7, 122.8, 122.5, 118.9, 115.9, 114.2, 111.2, 105.6, 67.8, 55.1, 36.9.
[0095] Example 7
[0096] Preparation of 3-(1H-benzo[d]imidazoline)-4-(3,4-dichlorophenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione
[0097]
[0098] The operation steps of this embodiment are as follows:
[0099] 1) Add 1.0 mmol 3,4-dichlorobenzaldehyde, 1.0 mmol 2-cyanomethylbenzimidazole and 1.0 mmol 4-hydroxycoumarin to a 50 mL three-necked flask with a spherical condenser, a thermometer and a magnetic stirrer containing 9 mL of an acidic deep eutectic solvent, and stir at room temperature until the mixture is uniformly mixed.
[0100] 2) Heat the three-necked flask in an oil bath under magnetic stirring, uniformly raise the temperature to 71° C., and maintain this temperature for 34 min. When the raw material spot disappears as detected by TLC (thin plate chromatography), the reaction is complete, and heating and stirring are stopped.
[0101] 3) The reaction solution was cooled to room temperature naturally, 12 mL of ethanol was added, and the mixture was allowed to stand for 4 h. The solid product was crushed and dried under vacuum at 80 ° C to constant weight, weighing 0.39 g. The main substance was identified by the HPLC retention value method as the target product 3-(1H-benzo[d]imidazoline)-4-(3,4-dichlorophenyl)-3,4-dihydropyran[3,2-c]chromene-2,5-dione, with a purity of 99.2%. The reaction yield was calculated to be 81%. After the filtrate was evaporated at 85 ° C to remove the ethanol, 3,4-dichlorobenzaldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin were directly added to carry out the next reaction.
[0102] The structural characterization data of the product 3-(1H-benzo[d]imidazoline)-4-(3,4-dichlorophenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione obtained in this example are as follows: white solid; 1 H NMR (400 MHz, DMSO-d 6 ): δ=5.15 (s, 1H), 7.17~7.19 (m, 2H), 7.36~7.58 (m, 6H), 7.67~7.71 (m, 1H), 7.84 (d, J=2.2Hz, 1H), 7.95 (d, J=8.2Hz, 1H), 12.19 (s, 2H); 13 CNMR (100 MHz, DMSO-d 6 ): δ=161.1, 160.0, 157.0, 152.9, 152.2, 146.0, 133.1, 131.1, 131.0, 130 .1, 129.8, 128.1, 125.1, 123.3, 123.2, 117.0, 114.6, 105.1, 66.8, 36.6.
[0103] Example 8
[0104] Preparation of 3-(1H-benzo[d]imidazoline)-4-(2,4-dichlorophenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione
[0105]
[0106] The operation steps of this embodiment are as follows:
[0107] 1) Add 1.0 mmol 2,4-dichlorobenzaldehyde, 1.0 mmol 2-cyanomethylbenzimidazole and 1.0 mmol 4-hydroxycoumarin to a 50 mL three-necked flask with a spherical condenser, a thermometer and a magnetic stirrer containing 10 mL of an acidic deep eutectic solvent, and stir at room temperature until the mixture is uniformly mixed.
[0108] 2) Heat the three-necked flask in an oil bath under magnetic stirring, uniformly raise the temperature to 83° C., and maintain this temperature for 39 min. When the raw material spot disappears as detected by TLC (thin plate chromatography), the reaction is complete, and heating and stirring are stopped.
[0109] 3) The reaction solution was cooled to room temperature naturally, 12 mL of ethanol was added, and the mixture was allowed to stand for 4 h. The solid product was crushed and dried under vacuum at 80 °C to constant weight, weighing 0.36 g. The main substance was identified by the HPLC retention value method as the target product 3-(1H-benzo[d]imidazoline)-4-(2,4-dichlorophenyl)-3,4-dihydropyran[3,2-c]chromene-2,5-dione, with a purity of 99.4%. The reaction yield was calculated to be 74%. After the filtrate was evaporated at 85 °C to remove the ethanol, 2,4-dichlorobenzaldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin were directly added to carry out the next reaction.
[0110] The structural characterization data of the product 3-(1H-benzo[d]imidazoline)-4-(2,4-dichlorophenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione obtained in this example are as follows: yellow solid; 1 H NMR (400 MHz, DMSO-d 6 ): δ=5.31 (s, 1H), 7.11~7.16 (m, 2H), 7.39~7.47 (m, 6H), 7.74 (t, J=7.6Hz, 1H), 7.94 (d, J=7.2Hz, 1H), 8.03 (d, J=8.0Hz, 1H), 11.91 (s, 2H); 13 C NMR (100 MHz, DMSO-d 6 ): δ=160.5, 159.4, 157.1, 152.8, 152.1, 138.2, 135.0, 133.2, 132.8, 132.2, 131.3, 130.1, 126.6, 124.9, 123.2, 122.8, 116.7, 113.7, 101.2, 65.1, 38.0.
[0111] Examples 9 to 13
[0112] In this example, the acidic deep eutectic solvent used in Example 1 was verified for repeated use and was reused 5 times (the raw materials and the amounts added, and the process parameters of each operation step were the same as in Example 1). The purity and yield of the product 3-(1H-benzo[d]imidazoline)-4-phenyl-3,4-dihydropyran[3,2-c]chromene-2,5-dione are shown in Table 1.
[0113] Table 1 Effect of the number of times the acidic deep eutectic solvent is reused on the purity and yield of the product 3-(1H-benzo[d]imidazoline)-4-phenyl-3,4-dihydropyrano[3,2-c]chromene-2,5-dione;
[0114] Corresponding embodiment Number of times the acidic deep eutectic solvent can be reused purity / % Yield / % Example 9 1 98.9 85 Example 10 2 98.7 85 Embodiment 11 3 98.6 83 Example 12 4 98.3 82 Embodiment 13 5 98.0 79
[0115] It can be seen from the data in Table 1 that the acidic deep eutectic solvent can be reused 4 times while ensuring that the purity of the product 3-(1H-benzo[d]imidazoline)-4-phenyl-3,4-dihydropyran[3,2-c]chromene-2,5-dione is greater than 98% or the yield reduction is less than 5%.
[0116] Embodiments 14 to 19
[0117] In this example, the acidic deep eutectic solvent used in Example 6 was verified for repeated use and was reused 6 times (the raw materials and the amounts added, and the process parameters of each operation step were the same as in Example 6). The purity and yield of the product 3-(1H-benzo[d]imidazoline)-4-(3-methoxyphenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione are shown in Table 2.
[0118] Table 2 Effect of the number of times the acidic deep eutectic solvent is reused on the purity and yield of the product 3-(1H-benzo[d]imidazoline)-4-(3-methoxyphenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione;
[0119] Corresponding embodiment Number of times the acidic deep eutectic solvent can be reused purity / % Yield / % Embodiment 14 1 99.3 71 Embodiment 15 2 99.0 70 Example 16 3 98.8 68 Embodiment 17 4 98.7 68 Embodiment 18 5 98.4 67 Embodiment 19 6 98.1 63
[0120] It can be seen from the data in Table 2 that the acidic deep eutectic solvent can be reused 5 times while ensuring that the purity of the product 3-(1H-benzo[d]imidazoline)-4-(3-methoxyphenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione is greater than 98% or the yield reduction is less than 5%.
[0121] Embodiment 20
[0122] In this example, the acidic low eutectic solvent in Example 13 was regenerated: 25 ml of ethyl acetate was added to the acidic low eutectic solvent from which ethanol had been evaporated, the mixture was refluxed under stirring for 30 min, and then separated with a separatory funnel to collect the lower liquid. Then, 25 ml of ethyl acetate was added thereto, the mixture was refluxed under stirring for 30 min, and then separated with a separatory funnel to collect the lower liquid. A total of three washing operations were performed, and the lower liquid obtained for the third time was vacuum dried at 75°C for 6 h to obtain a regenerated acidic low eutectic solvent, and its volume was measured to be 6.9 ml.
[0123] Examples 21 to 25
[0124] First, unused acidic deep eutectic solvent was added to the acidic deep eutectic solvent regenerated in Example 20 to make the volume reach 7 ml, and then it was reused and reused, and the steps were referred to Example 1 and Examples 9 to 13. Among them, the purity and yield of the product 3-(1H-benzo[d]imidazoline)-4-phenyl-3,4-dihydropyrano[3,2-c]chromene-2,5-dione are shown in Table 3.
[0125] Table 3 Effect of the number of times the regenerated acidic deep eutectic solvent is used on the purity and yield of the product 3-(1H-benzo[d]imidazoline)-4-phenyl-3,4-dihydropyrano[3,2-c]chromene-2,5-dione;
[0126] Corresponding embodiment Number of times the acidic deep eutectic solvent is used after regeneration purity / % Yield / % Embodiment 21 1 99.0 84 Embodiment 22 2 98.8 83 Embodiment 23 3 98.7 84 Embodiment 24 4 98.4 81 Embodiment 25 5 98.1 78
[0127] It can be seen from the purity and yield data in Table 3 that although the catalytic ability of the regenerated acidic deep eutectic solvent is inferior to that of the fresh acidic deep eutectic solvent, it can still be used and reused.
[0128] Embodiment 26
[0129] In this example, the acidic low eutectic solvent in Example 19 was regenerated: 40 ml of ethyl acetate was added to the acidic low eutectic solvent from which ethanol had been evaporated, the mixture was refluxed under stirring for 30 min, and then separated with a separatory funnel to collect the lower layer of liquid, and then 40 ml of ethyl acetate was added thereto, the mixture was continued to reflux under stirring for 30 min, and then separated with a separatory funnel to collect the lower layer of liquid, and a total of three washing operations were performed. The lower layer of liquid obtained for the third time was vacuum dried at 75°C for 6 h to obtain a regenerated acidic low eutectic solvent, and its volume was measured to be 10.7 ml.
[0130] Examples 27 to 32
[0131] First, unused acidic deep eutectic solvent was added to the acidic deep eutectic solvent regenerated in Example 26 to make the volume reach 11 ml, and then it was reused and reused, and the steps were referred to Example 6 and Examples 14 to 19. Among them, the purity and yield of the product 3-(1H-benzo[d]imidazoline)-4-(3-methoxyphenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione are shown in Table 4.
[0132] Table 4 Effect of the number of times the regenerated acidic deep eutectic solvent is used on the purity and yield of the product 3-(1H-benzo[d]imidazoline)-4-(3-methoxyphenyl)-3,4-dihydropyrano[3,2-c]chromene-2,5-dione;
[0133] Corresponding embodiment Number of times the acidic deep eutectic solvent is used after regeneration purity / % Yield / % Embodiment 27 1 99.3 71 Embodiment 28 2 99.2 71 Embodiment 29 3 99.0 69 Embodiment 30 4 98.7 70 Embodiment 31 5 98.5 67 Embodiment 32 6 98.2 63
[0134] It can be seen from the data in Table 4 that the regenerated acidic deep eutectic solvent can still be used and reused.
[0135] The preferred embodiments do not describe all the details in detail, nor do they limit the invention to the specific embodiments described. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.
Claims
1. A method for preparing a pharmaceutical intermediate 3-benzimidazolinium coumarin pyrone derivative by catalysis using an acidic deep eutectic solvent, It is characterized in that The chemical reaction formula of the preparation method is And the preparation method further comprises the following steps: Step 1: adding a preset amount of an acidic deep eutectic solvent into a flask equipped with a magnetic stirrer, a thermometer and a spherical condenser, and then adding a preset amount of aromatic aldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin, and stirring and mixing at room temperature; Step 2: Heat the reaction solution to 65-90°C in an oil bath while stirring, then keep the reaction at this temperature until the raw material point disappears, immediately stop stirring and heating, and keep the reaction for 27-46 minutes; Step 3: After the reaction solution is naturally cooled to room temperature, ethanol is added, the mixture is allowed to stand and filtered to separate the solid product, and the solid product is vacuum dried at 80° C. to a constant weight to obtain a 3-benzimidazolinylcoumarin-pyrone derivative.
2. A method for preparing a pharmaceutical intermediate 3-benzimidazolinium coumarin pyrone derivative catalyzed by an acidic deep eutectic solvent according to claim 1, It is characterized in that The molar ratio of the aromatic aldehyde, 2-cyanomethylbenzimidazole and 4-hydroxycoumarin in the step 1 is 1:1:
1.
3. A method for preparing a pharmaceutical intermediate 3-benzimidazolinium coumarin pyrone derivative catalyzed by an acidic deep eutectic solvent according to claim 1, It is characterized in that In the step 1, the volume of the acidic deep eutectic solvent in milliliters is 6 to 11 times the molar amount of the aromatic aldehyde in millimoles.
4. A method for preparing a pharmaceutical intermediate 3-benzimidazolinium coumarin pyrone derivative catalyzed by an acidic deep eutectic solvent according to claim 3, It is characterized in that The acidic low eutectic solvent is obtained by directly heating polyethylene glycol 200 and p-toluenesulfonic acid, wherein the molar ratio of polyethylene glycol 200 to p-toluenesulfonic acid is 1:
2.
5. A method for preparing a pharmaceutical intermediate 3-benzimidazolinium coumarin pyrone derivative catalyzed by an acidic deep eutectic solvent according to claim 2, It is characterized in that The aromatic aldehyde is any one of benzaldehyde, p-bromobenzaldehyde, m-bromobenzaldehyde, o-bromobenzaldehyde, p-chlorobenzaldehyde, m-methoxybenzaldehyde, 2,4-dichlorobenzaldehyde and 3,4-dichlorobenzaldehyde.
6. A method for preparing a pharmaceutical intermediate 3-benzimidazolinium coumarin pyrone derivative catalyzed by an acidic deep eutectic solvent according to claim 1, It is characterized in that The filtrate obtained by suction filtration in step 3 is subjected to rotary distillation at a temperature of 85° C. to remove ethanol, and then the acidic deep eutectic solvent is reused in the next round according to steps 1 to 3; During the repeated use of the acidic deep eutectic solvent, if the purity of the product 3-benzimidazolinium coumarin pyrone derivative is lower than 98% or the yield is reduced by more than 5% compared with the first use, the repeated use of the acidic deep eutectic solvent is stopped and it is regenerated.
7. A method for preparing a pharmaceutical intermediate 3-benzimidazolinium coumarin pyrone derivative catalyzed by an acidic deep eutectic solvent according to claim 6, It is characterized in that The method for regenerating the acidic deep eutectic solvent is as follows: A preset volume of ethyl acetate is added to the acidic low eutectic solvent which cannot be reused, and the mixture is refluxed under stirring for 30 minutes, and then the liquid is separated to collect the lower layer of liquid. Then, the same volume of ethyl acetate is added thereto, and the mixture is refluxed under stirring for another 30 minutes, and then the liquid is separated again to collect the lower layer of liquid. The washing operation is performed three times in sequence, and the lower layer of liquid obtained for the third time is vacuum dried at a temperature of 75°C for 6 hours to obtain a regenerated acidic low eutectic solvent.
8. A method for preparing a pharmaceutical intermediate 3-benzimidazolinium coumarin pyrone derivative catalyzed by an acidic deep eutectic solvent according to claim 7, It is characterized in that The volume usage of ethyl acetate used in the regeneration process of the acidic deep eutectic solvent is 3 to 5 times the volume of the acidic deep eutectic solvent used.
